At Adiso, we develop novel medicines to treat inflammatory diseases, prioritizing patient safety and efficacy. Our pipeline includes small molecules and single strain live biotherapeutic products (SS-LBPs) with innovative mechanisms of action. Currently, ADS024 (SS-LBP) is in Phase 1b studies for re...See more
Headquarter United States of America |
Year founded 2022 (2 years) |
Funding status Private |
Company type SME |